Clinical Guides
Combined Hormonal Contraception: Eligibility, Counselling and Safe Use
An India-contextualised educational guide to choosing, assessing and monitoring combined hormonal contraception; it supports clinical reasoning but is not a substitute for a current local protocol or an individual prescription.
MedNext Academy | 15 min read
Combined Hormonal Contraception: Eligibility, Counselling and Safe Use
An India-contextualised educational guide to choosing, assessing and monitoring combined hormonal contraception; it supports clinical reasoning but is not a substitute for a current local protocol or an individual prescription.
Summary
Combined hormonal contraception (CHC) combines an oestrogen with a progestogen. It includes combined oral pills, transdermal patches, vaginal rings and combined injectable preparations, although a method's availability, registration and public-sector supply differ by country and service. CHC prevents pregnancy principally by suppressing ovulation; it can also alter cervical mucus and the endometrium. It is a reversible option for people who want a user-controlled method and who have no contraindication to oestrogen. It does not protect against HIV or other sexually transmitted infections (STIs), so condoms remain important when STI prevention is needed.
The safe question is not simply whether a person wants a pill. It is whether the benefits of a combined method outweigh its risks for this particular person, at this point in life, using this formulation and with reliable follow-up. WHO's Medical Eligibility Criteria (MEC) gives a structured four-category framework for medical conditions and physiological states. The Selected Practice Recommendations (SPR) addresses how to start, use and manage methods once eligibility has been established. Both are global normative tools to be adapted by national programmes rather than copied as a personal prescription.
CHC can offer non-contraceptive benefits such as more predictable bleeding and reduced dysmenorrhoea for some users, but those benefits do not cancel a contraindication. Venous thromboembolism, arterial events, hypertension, migraine with aura, postpartum state, smoking at older age, active serious liver disease, breast cancer and interacting medicines require deliberate assessment. A new symptom, a changed medical history or a desire for pregnancy should prompt review. This guide teaches a safety-first consultation; it does not provide unsupervised initiation, switching or missed-dose instructions.
How Common Is It?
Contraceptive use is common, but a single prevalence figure cannot responsibly describe all Indian states, age groups, rural and urban communities or service settings. Method choice is shaped by fertility intention, partner support, privacy, cost, menstrual preferences, availability, past experience and confidence in accessing care. Public-health reporting may count a method supplied, whereas a clinical consultation must establish whether it is being used correctly, tolerated and continued by informed choice. A method that is theoretically effective but cannot be obtained or used consistently may not be the best method for that person.
Combined oral contraception is one component of a broader method mix. CHC is often discussed alongside condoms, progestogen-only methods, implants, intrauterine contraception, fertility-awareness methods and permanent contraception. These methods are not interchangeable: their mechanisms, effectiveness with typical use, contraindications, bleeding patterns, need for procedures and STI protection differ. A good clinician avoids framing a combined pill as the default for all young people or as the only reversible option.
Frequency should not obscure safety. Most CHC users will not experience a serious adverse event, but rare thrombotic or arterial harms matter because they can be severe and because risk rises in particular clinical contexts. The appropriate response is careful eligibility screening, informed counselling and clear safety-netting, not fear-based denial of contraception. Similarly, breakthrough bleeding and nausea are common reasons for discontinuation but do not automatically indicate harm or treatment failure.
For examinations and clinical practice, distinguish population-level method availability from individual medical eligibility. WHO MEC categories are applied to a person's conditions and characteristics, potentially more than one at a time, while the final service decision also depends on local protocols and clinical judgement.
Risk Factors
The risk assessment for CHC is principally an assessment of oestrogen-related thrombotic, vascular and other medical risk. Ask about any previous deep-vein thrombosis or pulmonary embolism, known thrombophilia, stroke, ischaemic heart disease, severe or uncontrolled hypertension, migraine with aura, major surgery with prolonged immobilisation, smoking and age, current or previous breast cancer, serious liver disease and unexplained vaginal bleeding. A history of diabetes, obesity, dyslipidaemia, postpartum status, breastfeeding and family history may modify assessment; they should be interpreted through the current MEC table rather than by a simplistic checklist.
Ask specifically about pregnancy possibility, last menstrual bleeding, recent birth, miscarriage or abortion, breastfeeding, a new baby or a planned procedure. Eligibility changes rapidly around pregnancy and the postpartum period because baseline clotting risk and breastfeeding considerations are time-sensitive. Never infer safety from a patient looking well or having used a pill before. Confirm the exact product, prior adverse effects and whether there has been a change in blood pressure, migraine pattern, smoking, mobility or medicines since the previous prescription.
Medication review is essential. Enzyme-inducing medicines and some antiretroviral, antiseizure, tuberculosis or herbal treatments can reduce hormonal contraceptive effectiveness or change risk. The correct action is to check the current product information and specialist or local family-planning advice, not to guess from a medicine class or to advise stopping a necessary treatment. Ask about over-the-counter remedies and traditional products without judgement.
Risk counselling must be equitable. Adolescence, disability, HIV status, marital status or a history of sexual activity are not automatic reasons to deny contraception. The person should receive confidential, voluntary, non-coercive counselling, with an accessible alternative offered whenever CHC is unsuitable or unacceptable.
Diagnosis
A CHC consultation is not a diagnosis of a disease, but it requires a structured clinical assessment to establish medical eligibility, exclude urgent problems and identify the person's contraceptive goal. Start by clarifying whether the request is for pregnancy prevention, cycle control, dysmenorrhoea, acne, treatment alongside another condition, emergency contraception follow-up or a switch from another method. Do not let a request for a prescription bypass assessment of possible pregnancy, cardiovascular symptoms, infection risk or a cause of abnormal bleeding.
History
Ask about pregnancy possibility, date and character of the last menstrual period, unprotected intercourse, recent emergency contraception, breastfeeding, recent pregnancy outcome and desire for future fertility. Record current and previous contraceptive methods, adherence difficulties, bleeding pattern, pelvic pain, headaches and any symptoms suggestive of thrombosis or arterial disease. Take a focused history of blood pressure disease, migraine including aura, venous or arterial thrombosis, diabetes complications, liver disease, cancer, smoking and mobility. Review medicines, allergies, family history where relevant, sexual health, STI risk and condom use. Ask what information or privacy support the person needs to make a voluntary choice.
Examination
Measure blood pressure with an appropriately sized cuff and repeat or arrange confirmation when elevated. Record weight or body mass index when it will inform assessment or counselling, but do not use body size alone to shame or arbitrarily refuse care. Check pulse and undertake targeted cardiovascular, neurological, abdominal or breast assessment only when history or symptoms indicate it. A pelvic examination, cervical screening test, breast examination, routine laboratory panel or pregnancy test is not a universal precondition for every CHC request; investigations should answer a clinical question. Obtain informed consent, offer a chaperone where appropriate and use trauma-informed practice.
Investigations
Use a pregnancy test when pregnancy status cannot be established from history and timing, and assess urgently if pain, bleeding, syncope or ectopic-pregnancy concern is present. Repeat blood-pressure measurement or arrange hypertension assessment when needed. Lipids, glucose, liver tests, thrombophilia testing, imaging or specialist review are targeted to symptoms, known disease or a relevant history, not blanket screening tests. A new focal neurological deficit, acute dyspnoea, chest pain or unilateral leg swelling requires urgent diagnostic assessment rather than routine contraceptive follow-up.
Differential Diagnosis
Symptoms arising during CHC use need a differential diagnosis rather than automatic attribution to hormones. Nausea, breast tenderness, mood change and unscheduled bleeding may be method-related, but pregnancy, infection, missed tablets, medication interactions, structural gynaecological disease and systemic illness can coexist. Confirm what was actually used, when it was started, whether doses were missed, any vomiting or diarrhoea affected absorption, and whether an interacting medicine was introduced. Do not assume that any bleeding means the method has failed or that all bleeding is harmless.
New headache requires differentiation between a familiar non-focal headache and migraine with aura, severe hypertension, stroke, cerebral venous thrombosis, meningitis or another urgent neurological condition. Aura is a focal neurological phenomenon preceding or accompanying migraine; vague dizziness or ordinary visual strain should not be casually labelled aura, but possible aura warrants careful assessment before continuing an oestrogen-containing method. New chest pain, breathlessness, haemoptysis, unilateral leg pain or swelling may signal venous thromboembolism and needs urgent evaluation.
Abnormal bleeding may reflect pregnancy including ectopic pregnancy, cervicitis or other STI, cervical pathology, polyps, fibroids, endocrine disturbance, perimenopause, medication effects or poor adherence. Pelvic pain with fever, discharge, cervical motion tenderness or systemic illness suggests infection or another acute pelvic diagnosis, not merely a side effect. Heavy bleeding with dizziness or haemodynamic compromise is an emergency.
A patient who becomes pregnant while using CHC needs confirmation of pregnancy location and an individual medication review. CHC is not used to support an established pregnancy, but an inadvertent exposure should be discussed calmly through an obstetric service rather than provoking unsupported claims of certain fetal harm. The diagnostic aim is to avoid missed emergencies and to select a safer method if CHC no longer fits.
Management
Management begins with person-centred choice. Explain the available reversible and permanent methods in language the person understands, including their expected bleeding pattern, need for daily or scheduled action, procedure requirements, return to fertility, privacy, STI protection and medical restrictions. Ask whether avoiding pregnancy, reducing bleeding or pain, maintaining confidentiality, breastfeeding, acne control or ease of use is the main priority. A person may choose a non-CHC method even when medically eligible for CHC; autonomy includes the option to decline every method.
If CHC is appropriate after a current eligibility assessment, provide method-specific counselling from the verified local product information and WHO SPR-adapted national pathway. This includes how to start, what backup protection is needed if relevant, what to do with missed or delayed use, what to do after vomiting or diarrhoea for oral methods, expected early bleeding changes and when to seek help. Do not give a universal schedule because instructions differ by formulation and active-hormone pattern. Provide a written or accessible plan and a route for questions.
Encourage condoms when STI prevention is relevant; CHC does not prevent HIV, gonorrhoea, chlamydia or other STIs. Offer or arrange STI and HIV testing according to risk and local guidance, but do not make testing a coercive prerequisite for contraception unless clinically necessary. Discuss emergency contraception after unprotected intercourse or method failure using a current protocol, and explain that it is distinct from continuing CHC.
Arrange review when blood pressure is elevated, symptoms change, bleeding is troublesome, adherence is difficult, a medicine changes or the person wishes to stop. If CHC is medically unsuitable, explain why without alarm and offer a safe alternative such as a progestogen-only or non-hormonal method, with method-specific assessment. Avoid stopping a necessary method abruptly without discussing immediate pregnancy protection and an alternative plan.
Prescribing Information
This section is a prescribing safety framework, not an individual regimen. Before issuing an oestrogen-containing product, document the indication, pregnancy assessment, blood pressure, relevant MEC conditions, migraine history, smoking, thrombotic and cardiovascular history, postpartum and breastfeeding status, medicine interactions, allergies and the person's informed preference. Check the current national protocol, local formulary and product information for the exact formulation, initiation advice, missed-use instructions and contraindications. Brand names, pack designs and availability change; this guide deliberately avoids recommending a commercial product or a fixed dose.
WHO MEC classifies conditions from category 1, where there is no restriction, to category 4, where the method poses an unacceptable health risk. Category 2 usually permits use with consideration of the balance of benefits and risks; category 3 usually means risks outweigh advantages and another method is generally preferable. Multiple conditions must be considered together. A category is not a substitute for professional judgement, local scope of practice or referral when the history is uncertain.
Counsel on common effects such as nausea, breast tenderness, headache and altered bleeding. Explain urgent warning symptoms in plain language: severe or persistent chest pain or breathlessness, coughing blood, one-sided painful leg swelling, a severe new headache or focal neurological symptoms, sudden visual change, jaundice, or heavy bleeding with collapse. These symptoms need urgent medical assessment and should not be managed by merely changing pills remotely.
Document the method, quantity, counselling, condoms or STI advice where applicable, interaction review, warning symptoms, follow-up route and exact plan for stopping or changing methods. Refills should not become automatic if blood pressure, medical history or medication exposure has changed. In a patient with potentially contraindicating symptoms, defer routine CHC continuation until appropriate assessment has clarified safety.
When to Refer
Refer urgently or send to emergency care for suspected venous thromboembolism, pulmonary embolism, stroke, acute coronary syndrome, severe hypertension with symptoms, severe new neurological symptoms, significant jaundice, heavy bleeding with instability, severe abdominal or pelvic pain with pregnancy possibility, or a patient who is acutely unwell. Do not wait for a routine contraceptive appointment, a pregnancy test result that is delayed, or a period of self-observation when these features are present.
Refer for specialist or experienced family-planning, gynaecology, neurology, cardiology, haematology, hepatology or obstetric input when eligibility is uncertain because of previous thrombosis, known thrombophilia, complex cardiac disease, migraine with possible aura, significant hypertension, active or previous cancer, liver disease, complex drug interactions or complex postpartum circumstances. The destination depends on the question: a clinician may need contraceptive-method selection, evaluation of a symptom, or both.
Refer or investigate abnormal bleeding that is persistent, heavy, occurs after sex, follows a previously stable pattern, or is associated with pain, pregnancy possibility, anaemia, discharge, a mass or an abnormal cervix. Persistent symptoms require diagnostic evaluation even if CHC is stopped. A person who cannot use or does not want CHC should be offered an alternative method rather than being told to return only after specialist review, unless an acute safety issue demands it.
Practical referral is part of quality. Send the exact product, start date, missed-use history, blood-pressure readings, symptoms, medical history, medicines, pregnancy test if done and reason for referral. Address language, disability, confidentiality, travel and cost barriers so a referral does not become a hidden denial of care.
Red Flags
New focal neurological symptoms, migraine with aura or a severe unusual headache are red flags in a CHC user because oestrogen exposure may be unsafe in some vascular contexts. Sudden chest pain, unexplained shortness of breath, coughing blood, fainting, one-sided painful leg swelling or severe upper-abdominal pain require urgent assessment for potentially serious causes. Do not reassure a patient on the basis that they are young, physically fit or have used CHC previously.
Heavy vaginal bleeding with dizziness, syncope, pallor or haemodynamic compromise needs urgent care. So do pregnancy possibility plus pelvic pain, shoulder-tip pain, fainting or bleeding, because ectopic pregnancy must be considered. Fever, purulent discharge, severe pelvic tenderness, peritonism or a toxic appearance warrants urgent assessment for infection or another acute abdominal condition.
Jaundice, dark urine, marked pruritus, severe right-upper-quadrant pain or a new liver diagnosis requires prompt review of hormonal medication and clinical assessment. New hypertension, a major operation with planned immobility, a new smoking pattern, starting an enzyme-inducing medicine or a significant change in migraine should trigger reassessment before CHC is continued.
Safeguarding and consent are also safety issues. Coercion by a partner or family, fear of disclosure, sexual violence, inability to consent, or a request made under pressure should prompt a confidential, trauma-informed response and the appropriate local safeguarding pathway. Contraception must remain voluntary. A clinician should never use CHC access to demand a pelvic examination, STI test or disclosure of private information that is not clinically necessary.
Indian Clinical Context
The National Health Mission (NHM) maintains family-planning guidance and hosts a reference manual on oral contraception within the Government of India family-planning programme. That manual distinguishes combined oral contraception from progestogen-only and emergency oral methods and emphasises regular use and lack of STI protection. The current NHM guideline index confirms that these resources remain part of the programme library, but an online index is not a substitute for checking the current state, district or facility protocol before prescribing. This guide therefore does not assert universal local supply, cost, eligibility cut-offs or an Indian brand.
WHO MEC and SPR are global normative guidance. WHO explicitly states that national programmes adapt the guidance to country context, provider skills and available resources. For an Indian learner, that means using MEC to structure clinical reasoning while following current Indian law, approved product information, NHM or state programme instructions and the local referral pathway. A dated NHM resource may remain educationally useful yet require verification for a current stock, pack or service-delivery instruction.
Access may be affected by privacy, gender norms, travel, digital access, menstrual stigma, literacy, disability and fear that a request for contraception will be judged. Offer confidential counselling, translated or accessible written information, a chance to speak without an accompanying person if safe, and a method that fits the person's circumstances. Do not assume that marriage, parity, religion or a partner's preference determines contraceptive eligibility.
Indian services vary in their ability to measure blood pressure, obtain same-day pregnancy testing, assess migraine or thrombosis risk, or offer alternatives. The minimum safe response is not to dispense blindly: identify red flags, assess blood pressure and pregnancy possibility, document relevant history, explain STI protection limits, use the current local protocol and refer when eligibility is uncertain.
NMC Competency Mapping
The National Medical Commission's Competency Based Medical Education Curriculum 2024 expects graduates to provide reproductive-health care, communicate respectfully, use investigations appropriately, prescribe safely and recognise when referral is needed. Combined hormonal contraception brings these skills together: it is not a memorisation exercise about one pill but an encounter involving autonomy, pregnancy intention, medical eligibility, risk communication and continuity of care.
At the Know level, learners should define CHC, distinguish it from progestogen-only and emergency methods, describe that it contains oestrogen and progestogen, and explain the difference between contraceptive efficacy and STI prevention. They should understand the purpose of WHO MEC categories and why global guidance requires country-level adaptation. They should recognise that pregnancy prevention, menstrual management and patient preference can all contribute to method choice.
At the Know How level, learners should take a focused history, check blood pressure, identify migraine with aura, thrombosis, postpartum timing, major medicine interactions and red flags, and formulate a safe alternative when CHC is unsuitable. They should be able to explain common effects, urgent warning symptoms, condoms and the need for method-specific instructions without using fear or stigma.
At the Show How level, a learner should obtain informed consent, preserve confidentiality, document a risk assessment and safety-netting plan, and arrange referral for uncertainty or acute symptoms. No invented condition-specific NMC code is used here; institutions should map this guide to their currently approved local competency ledger and assessment process.
Key Exam Pearls for NEET PG
Combined hormonal contraception contains both oestrogen and progestogen; progestogen-only pills, implants, injectables and LNG-IUS are different method classes. CHC does not protect against STIs, so condoms are needed when STI prevention is relevant. Never confuse contraception counselling with permission to omit HIV or STI prevention advice.
WHO MEC asks who can safely use a method. Category 1 means no restriction; category 2 means advantages generally outweigh risks; category 3 means risks usually outweigh advantages; category 4 means unacceptable health risk. Apply all relevant conditions together and adapt the guidance to the local programme rather than treating a category as a stand-alone prescription.
Before CHC, assess pregnancy possibility, blood pressure, migraine including aura, smoking, thrombotic and cardiovascular history, postpartum or breastfeeding status, serious liver disease, breast cancer and medicine interactions. A pelvic examination, Pap test, routine thrombophilia panel or laboratory screen is not automatically required for every request; tests should answer a clinical question.
Remember urgent warning patterns: unilateral painful leg swelling, chest pain or breathlessness, haemoptysis, severe new headache or focal neurological symptoms, sudden visual disturbance, jaundice, severe abdominal pain and heavy bleeding with instability. These need assessment for serious pathology, not a remote refill or an empirical pill switch.
Method-specific initiation, missed-use and backup advice vary by formulation. In an exam answer, state that the current WHO SPR-adapted or local product protocol must be used. In clinical practice, give written instructions and a safe alternative if eligibility is uncertain or CHC is contraindicated.
Frequently Asked Questions
Does combined hormonal contraception protect against sexually transmitted infections?
No. Combined hormonal contraception prevents pregnancy but does not prevent HIV, gonorrhoea, chlamydia, syphilis or other sexually transmitted infections. Condoms should be discussed when STI prevention is relevant, alongside testing and treatment based on risk and local guidance. Using both a condom and an effective contraceptive method can address different goals without implying distrust or stigma.
Why must blood pressure be checked before combined hormonal contraception?
Blood pressure is part of the safety assessment because hypertension can change the balance of risks and benefits of an oestrogen-containing method. A single unexpected high reading should be checked appropriately, but it should not be ignored. The clinician also considers symptoms, cardiovascular history, migraine, smoking, medicines and pregnancy-related context before deciding whether combined hormonal contraception is suitable.
Can a person with migraine use combined hormonal contraception safely?
The answer depends on the type of migraine and the person's wider vascular risk. Migraine with aura requires particular caution and evaluation under current medical-eligibility guidance. A new severe headache, focal neurological symptom or uncertain history should not be managed by an automatic refill. Clarifying the headache pattern and offering a safer alternative method may be necessary.
What should happen if troublesome bleeding starts on CHC?
First establish how the method has been used, whether doses were missed, whether vomiting, diarrhoea or medicines could affect it, and whether pregnancy or infection is possible. Early unscheduled bleeding can occur, but persistent, heavy, postcoital or painful bleeding needs assessment for other causes. Do not repeatedly change or stop hormonal methods without advice about immediate pregnancy protection and follow-up.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic